{"id":"sofosbuvir-daclatasvir-ribavirin","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Fatigue"},{"rate":"15-30","effect":"Headache"},{"rate":"10-25","effect":"Nausea"},{"rate":"10-20","effect":"Anemia (ribavirin-related)"},{"rate":"10-15","effect":"Insomnia"},{"rate":"5-15","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase, essential for HCV replication. Daclatasvir is an NS5A inhibitor that blocks viral protein function and replication complex formation. Ribavirin is a nucleoside analog with broad antiviral activity that enhances the efficacy of the direct-acting antivirals and may boost immune response.","oneSentence":"This combination inhibits hepatitis C virus replication by blocking the NS5B polymerase (sofosbuvir), NS5A protein (daclatasvir), and reducing viral load through ribavirin's direct antiviral activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:22.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent, likely genotypes 1-6)"},{"name":"Treatment-naïve and treatment-experienced HCV patients"}]},"trialDetails":[{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT04729153","phase":"","title":"Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02","conditions":"Covid19","enrollment":100},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT03283176","phase":"","title":"Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals","enrollment":50},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT04387526","phase":"PHASE2, PHASE3","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2016-04-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":946},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT03481036","phase":"NA","title":"DAA Therapy in Pediatric Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT02304159","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics","status":"COMPLETED","sponsor":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","startDate":"2015-01","conditions":"Hepatitis C, Cirrhosis","enrollment":39},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT03665766","phase":"","title":"Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-05-15","conditions":"Liver Transplantation","enrollment":126},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT02673489","phase":"PHASE3","title":"A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-15","conditions":"Hepatitis C","enrollment":106},{"nctId":"NCT02482077","phase":"PHASE4","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":112},{"nctId":"NCT03186313","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Egyptian Liver Hospital","startDate":"2016-09","conditions":"Hepatitis C","enrollment":72},{"nctId":"NCT03318887","phase":"","title":"Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-02-01","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT02772744","phase":"","title":"Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2017-11-01","conditions":"Hepatitis C","enrollment":250},{"nctId":"NCT03296930","phase":"PHASE4","title":"Effect Of DAAs For Treatment Of HCV On Normal Kidney","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-10-01","conditions":"Antiviral Drug Adverse Reaction","enrollment":100},{"nctId":"NCT02628717","phase":"","title":"Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-07","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":558},{"nctId":"NCT03268317","phase":"","title":"Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-01","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03247296","phase":"","title":"Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir","status":"UNKNOWN","sponsor":"MTI University","startDate":"2017-02-28","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT03241823","phase":"","title":"Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-12-01","conditions":"Hepatitis C, Liver Cirrhosis","enrollment":100},{"nctId":"NCT03226717","phase":"","title":"Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-08-10","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":"Hepatitis C, Chronic, Hemoglobinopathies","enrollment":168},{"nctId":"NCT03133065","phase":"PHASE4","title":"Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09","conditions":"Liver Transplantation","enrollment":89},{"nctId":"NCT02032875","phase":"PHASE3","title":"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT02319031","phase":"PHASE3","title":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-02","conditions":"Hepatitis C","enrollment":53},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02771405","phase":"PHASE3","title":"Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02531269","phase":"","title":"Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03","conditions":"Hepatitis C","enrollment":249},{"nctId":"NCT02097966","phase":"","title":"EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT02551861","phase":"PHASE2","title":"A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2015-12","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01359644","phase":"PHASE2","title":"Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-06","conditions":"Chronic Hepatitis C","enrollment":350},{"nctId":"NCT02469012","phase":"NA","title":"Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy","status":"UNKNOWN","sponsor":"University of Wuerzburg","startDate":"2014-10","conditions":"Hepatitis C, Chronic","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sofosbuvir + Daclatasvir + Ribavirin","genericName":"Sofosbuvir + Daclatasvir + Ribavirin","companyName":"Egyptian Liver Hospital","companyId":"egyptian-liver-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits hepatitis C virus replication by blocking the NS5B polymerase (sofosbuvir), NS5A protein (daclatasvir), and reducing viral load through ribavirin's direct antiviral activity. Used for Chronic hepatitis C virus infection (genotype-dependent, likely genotypes 1-6), Treatment-naïve and treatment-experienced HCV patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}